ViroGates A/S
CCPH:VIRO8.00
DKK
0.00
(0.00%)
ISIN
DK0061030574
Return %
Stock
S&P 500
1Y
-37.74
14.20
3Y
-39.33
81.12
5Y
-93.56
68.34
Capital Structure
DKK
•
in mil. unless spec.Working Capital
DKK
•
in mil. unless spec.Growth Rates
DKK
•
in mil. unless spec.Quarterly Revenue
DKK
•
in mil. unless spec.Quarterly Earnings Per Share
DKK
•
in mil. unless spec.Quarterly Dividends Per Share
DKK
•
in mil. unless spec.Company Description
- CEO
- Jakob Knudsen
- Full Time Employees
- 7
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- BanevAenget 13 Birkerod CR Denmark 3460
- IPO Date
- Jun 26, 2018
- Website
- virogates.com
- Similar Companies
- Business
- ViroGates A/S ViroGates A/S is a Denmark-based international in vitro diagnostics company that develops and markets proprietary blood tests under the suPARnostic® brand to measure the suPAR biomarker, which indicates chronic inflammation levels and predicts disease presence, severity, progression, and mortality risk across conditions including cardiovascular disease, type 2 diabetes, cancer, infectious diseases, kidney disease, and respiratory issues; the product line comprises suPARnostic® TurbiLatex for turbidimetric platforms compatible with leading analyzers from Roche, Siemens, Abbott, and Beckman Coulter, suPARnostic® Quick Triage for point-of-care testing, and suPARnostic® ELISA assays, enabling results in under 20 minutes to support patient triage in emergency departments, guide treatments such as sepsis and COVID-19 therapies, and monitor biological age and lifestyle interventions in health and longevity clinics. Founded in 2001 based on research from Hvidovre University Hospital and headquartered in Birkerød north of Copenhagen in Medicon Valley, the company operates sales forces in Spain, France, and Benelux while serving over 20 countries worldwide through distributors in Europe, North America, the Middle East, East Asia, Southeast Asia, and East Africa; it targets hospitals for acute care triage, clinical laboratories and health clinics for longevity and preventive health monitoring, and research institutions leveraging over 1,000 peer-reviewed publications on suPAR. Recent strategic developments include a October 2024 distribution agreement with SuPAR Health LLC to launch suPARnostic® ELISA as a lab-developed test in the US longevity market, accompanied by a directed share issuance of 1,289,510 shares to SuPAR Remedy LLC raising DKK 8.2 million; an agreement with GENSPEED Biotech GmbH to refine the suPARnostic® POC+ device for clinical use with results expected in H1 2025; ongoing collaboration with Swedish Orphan Biovitrum AB (Sobi) including a US FDA Q-Submission meeting in April 2024 to pursue 510(k)/De Novo clearance for suPARnostic® TurbiLatex; and a reorganization of the marketing and sales department to prioritize the health and longevity segment amid a 12% revenue decline to DKK 4.9 million in 2024.